According to NICE guideline NG28 (Type 2 diabetes in adults: management), GLP-1 receptor agonists like Ozempic are usually considered after first-line therapies have not achieved glycaemic targets
Glucose Lowering Liraglutide was the first long-acting GLP-1RA to become available for the treatment of T2D, receiving market authorization in 2009 in the EU (137), 4 years after the short-acting GLP-1RA, exenatide, was first approved in the US (138)
Expert Opinions : Medical experts, while acknowledging the potential link between these medications and gastroparesis, also note the possibility of other causes, such as underlying medical conditions
Placella at our Gilbert clinic offers several advantages: By partnering with Dr
A high-quality, nutrient-heavy meal replacement can help fill the gap without skipping meals